Phase I Evaluation of Etanercept and Repeated Contrast Ultrasound Safety in Alzheimer’s Disease Patients

The primary objective of this study is to evaluate the **safety** of a therapeutic strategy that combines the administration of etanercept with repeated contrast ultrasound in patients diagnosed with **Alzheimer's disease**. This investigation is clinically relevant as it aims to assess the potential risks associated with this combined approach, which could inform future therapeutic protocols and improve patient outcomes in managing Alzheimer's disease.

The clinical trial involves participants diagnosed with **Alzheimer's disease**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population is noted to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed the total number of participants involved in the study.

The clinical trial is designed to evaluate the safety of a strategy combining **etanercept** administration with repeated contrast ultrasound in patients with **Alzheimer's disease**. This study is a phase I trial, which is expected to commence recruitment on April 1, 2025, and conclude by October 2, 2027. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group receiving etanercept and contrast ultrasound or a control group. The double-blind nature of the study ensures that neither the participants nor the investigators are aware of the group assignments, minimizing bias.

The trial will include several study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo baseline assessments before the initiation of the treatment protocol. Throughout the study, participants will attend regular follow-up visits to monitor safety, efficacy, and any adverse events. These visits will include clinical evaluations, laboratory tests, and imaging studies as necessary. The end-of-study visit will occur after the final treatment cycle, where comprehensive assessments will be conducted to evaluate the overall outcomes and safety of the intervention.

Participant involvement is expected to last for the duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent, or non-compliance with study procedures. The trial's design and procedures are structured to ensure the collection of high-quality data while prioritizing participant safety and adherence to ethical standards.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied, the trial's main objective, or any other pertinent details that would typically be included in a clinical trial description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on April 1, 2025, with an estimated completion date of October 2, 2027. The efficacy of the investigational treatment will be evaluated using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data, adhering to the standards expected in a Phase 3 clinical trial. The study will be conducted over a defined period, allowing for the systematic assessment of treatment effects. The trial's design and execution will be aligned with regulatory requirements to ensure the reliability and validity of the efficacy outcomes.